These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37855644)

  • 1. Severe Cushing's syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat.
    Hána V; Brutvan T; Krausová A; Kršek M; Hána V
    Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 37855644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy.
    Malik RB; Ben-Shlomo A
    AACE Clin Case Rep; 2022; 8(6):267-270. PubMed ID: 36447826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results.
    Antonini S; Brunetti A; Zampetti B; Boeris D; Saladino A; Cesare Cozzi R
    Endocrinol Diabetes Metab Case Rep; 2022 Nov; 2022():. PubMed ID: 36515363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unique case of ectopic Cushing's syndrome from a thymic neuroendocrine carcinoma.
    Lawrence L; Zhang P; Choi H; Ahmad U; Arrossi V; Purysko A; Makin V
    Endocrinol Diabetes Metab Case Rep; 2019 Feb; 2019():. PubMed ID: 30802210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.
    Beauregard C; Dickstein G; Lacroix A
    Treat Endocrinol; 2002; 1(2):79-94. PubMed ID: 15765624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Median 10 years follow-up of patients with covert Cushing's syndrome: a case series.
    Najafipour F; Bahrami A; Niafar M; Houshyar J; Halimi M; Sadra V
    J Med Case Rep; 2021 Oct; 15(1):514. PubMed ID: 34635153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review.
    Iwayama H; Hirase S; Nomura Y; Ito T; Morita H; Otake K; Okumura A; Takagi J
    BMC Endocr Disord; 2018 Mar; 18(1):19. PubMed ID: 29587720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy.
    Amodru V; Brue T; Castinetti F
    Endocrinol Diabetes Metab Case Rep; 2021 Dec; 2021():. PubMed ID: 34877930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat.
    Heleno CT; Hong SPD; Cho HG; Kim MJ; Park Y; Chae YK
    Case Rep Oncol; 2023; 16(1):124-128. PubMed ID: 36876215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
    Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
    Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osilodrostat - an emerging drug for the medical management of Cushing's disease.
    Witek P; Mehlich A; Stasiewicz A; Jawiarczyk-Przybyłowska A; Bolanowski M
    Endokrynol Pol; 2022; 73(2):371-374. PubMed ID: 35381096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRKAR1A-negative familial Cushing's syndrome: two case reports.
    Lim LL; Kitan N; Paramasivam SS; Ratnasingam J; Ibrahim L; Chan SP; Tan AT; Vethakkan SR
    J Med Case Rep; 2015 Dec; 9():277. PubMed ID: 26619967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.